A Gram-negative, microaerophilic genus within the Proteobacteria phylum (family Sutterellaceae). The primary species S. wadsworthensis is classified as a pathobiont due to its IgA-degrading capacity and associations with neurodevelopmental and inflammatory conditions. However, Sutterella shows notably contradictory findings across studies, being enriched in some disease contexts and depleted in others, complicating its classification.
Role in Gut Ecosystem
- Adheres to intestinal epithelial cells and resides within the mucosal layer, positioning it in close contact with the host immune system.
- Produces IgA proteases that degrade secretory immunoglobulin A, the primary antibody defending mucosal surfaces. This IgA-degrading activity may impair mucosal immunity and facilitate pathogen invasion or immune dysregulation.
- Relatively bile-resistant, allowing colonization of the small intestine and colon.
- Does not produce significant short chain fatty acids, distinguishing it from beneficial anaerobes in similar ecological niches.
Disease Associations
Autism Spectrum Disorder
- Consistently enriched in ASD across multiple studies, making it one of the more reproducible ASD-associated taxa [bezawada 2020 asd gut microbiota children systematic review].
- IgA degradation may contribute to the increased gut permeability ("leaky gut") reported in ASD children, potentially allowing microbial metabolites and bacterial products to cross the gut barrier and affect the CNS via the gut brain axis.
Multiple Sclerosis
- Increased in MS patients on immunomodulatory therapy (treatment effect rather than disease effect), suggesting that immune suppression may create a niche for Sutterella expansion [jangi 2016 gut microbiome alterations ms].
- May benefit from reduced IgA pressure under immunomodulatory treatment, consistent with its IgA-degrading phenotype.
Inflammatory Bowel Disease
- Contradictory findings: enriched in some IBD cohorts (particularly in mucosal biopsies) but depleted in others (stool-based studies). This inconsistency may reflect differences between mucosal and luminal sampling, disease phase, or IBD subtype.
- Detected in intestinal biopsies of patients with Crohn's disease and ulcerative colitis, suggesting mucosal colonization preference.
Cardiovascular and Metabolic Disease
- Identified in MR analyses examining gut microbiota-lipid and gut microbiota-CVD relationships, though effect sizes are modest [teng 2024 gut microbiome lipids mr, dai 2024 gut microbiota cvd bidirectional mr].
Key Metabolites
- IgA protease -- degrades secretory IgA; impairs mucosal immune defense
- No significant SCFA production documented
Mechanistic Considerations
- The IgA-degrading capacity of Sutterella provides a clear mechanistic link to mucosal immune impairment. In the healthy gut, secretory IgA coats commensal bacteria and neutralizes pathogens; its degradation could destabilize the entire mucosal immune equilibrium.
- The increase under immunomodulatory therapy in MS suggests Sutterella is normally kept in check by robust mucosal immunity, and its expansion may be a consequence rather than cause of immune dysregulation.
- As a Proteobacteria member, its enrichment may reflect the broader "Proteobacteria bloom" seen in inflammatory conditions.
Connections
- autism spectrum disorder -- enriched in ASD; IgA degradation may contribute to gut barrier dysfunction
- multiple sclerosis -- increased under immunomodulatory therapy
- Crohn's disease -- detected in intestinal biopsies; contradictory enrichment/depletion findings
- gut brain axis -- mucosal immune impairment may allow neuroactive metabolite translocation
- inflammation -- IgA degradation disrupts mucosal homeostasis
- dysbiosis -- Proteobacteria expansion as marker of inflammatory dysbiosis
- escherichia coli -- fellow Proteobacteria; both expand under inflammatory conditions
- akkermansia muciniphila -- both are mucosal-associated; potentially competing for mucosal niche